{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T05:41:14Z","timestamp":1773034874023,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"am","delay-in-days":317,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R03DA053252"],"award-info":[{"award-number":["R03DA053252"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research in Social and Administrative Pharmacy"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.sapharm.2024.04.019","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T15:45:53Z","timestamp":1715096753000},"page":"778-785","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["ASAP: A pharmacy-level intervention to increase nonprescription syringe sales to reduce bloodborne illnesses"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1762-7179","authenticated-orcid":false,"given":"B.E.","family":"Meyerson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Agley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.A.","family":"Crosby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.G.","family":"Bentele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Vadiei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.B.","family":"Linde-Krieger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.R.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Fine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.A.","family":"Eldridge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.sapharm.2024.04.019_bib1","article-title":"HIV infection risk, prevention, and testing behaviors among persons who inject drugs\u2014national HIV behavioral surveillance: injection drug use, 23 U.S. Cities","year":"2018","journal-title":"HIV Surveillance Special Report 24"},{"issue":"Suppl 2","key":"10.1016\/j.sapharm.2024.04.019_bib2","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1093\/cid\/cit300","article-title":"Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention","volume":"57","author":"Page","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.sapharm.2024.04.019_bib3","first-page":"1","article-title":"Prevalence and high risk behaviours associated with HCV testing among people who inject drugs: a systematic review and Meta-analysis","volume":"15","author":"Karimi","year":"2020","journal-title":"Subst Abuse Treat Prev Pol"},{"issue":"1","key":"10.1016\/j.sapharm.2024.04.019_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-020-8175-1","article-title":"A systematic review and meta-analysis of the prevalence of hepatitis C virus infection in people who inject drugs in Iran","volume":"20","author":"Behzadifar","year":"2020","journal-title":"BMC Publ Health"},{"issue":"10","key":"10.1016\/j.sapharm.2024.04.019_bib5","doi-asserted-by":"crossref","first-page":"e569","DOI":"10.1016\/S2352-3018(18)30176-0","article-title":"Dynamics of the HIV outbreak and response in Scott County, IN USA 2011-2015: a modeling study","volume":"5","author":"Gonsalves","year":"2018","journal-title":"The Lancet HIV"},{"key":"10.1016\/j.sapharm.2024.04.019_bib6","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(96)02536-6","article-title":"HIV incidence among injecting drug users in New York City syringe-exchange programmes","volume":"348","author":"Des Jarlais","year":"1996","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.sapharm.2024.04.019_bib7","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1007\/s10461-013-0593-y","article-title":"Effectiveness of structural-level needle\/syringe programs to reduce HCV and HIV infection among people who inject drugs: a systematic review","volume":"17","author":"Abdul-Quader","year":"2013","journal-title":"AIDS Behav"},{"issue":"5","key":"10.1016\/j.sapharm.2024.04.019_bib8","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/j.1360-0443.2009.02888.x","article-title":"Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews","volume":"105","author":"Palmateer","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.sapharm.2024.04.019_bib9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s12889-017-4210-2","article-title":"Effectiveness of needle and syringe programmes in people who inject drugs \u2013 an overview of systematic reviews","volume":"17","author":"Fernandes","year":"2017","journal-title":"BMC Publ Health"},{"key":"10.1016\/j.sapharm.2024.04.019_bib10","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.drugpo.2018.04.004","article-title":"Stigma at every turn: health services experiences among people who inject drugs","volume":"57","author":"Paquette","year":"2018","journal-title":"Int Drug Pol"},{"issue":"2021","key":"10.1016\/j.sapharm.2024.04.019_bib11","article-title":"I don't even want to go to the doctor when I get sick now: healthcare experiences and discrimination reported by People who Use Drugs, Arizona 2019","volume":"93","author":"Meyerson","year":"2021","journal-title":"Int J Drug Pol"},{"key":"10.1016\/j.sapharm.2024.04.019_bib12","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1007\/s10461-021-03304-x","article-title":"Living at the confluence of stigmas: PrEP awareness and feasibility among people who inject drugs in two predominantly rural states","volume":"25","author":"Carter","year":"2021","journal-title":"AIDS Behav"},{"key":"10.1016\/j.sapharm.2024.04.019_bib14","doi-asserted-by":"crossref","first-page":"F59","DOI":"10.1097\/00002030-199708000-00001","article-title":"Needle exchange is not enough: lessons from the Vancouver injecting drug use study","volume":"11","author":"Strathdee","year":"1997","journal-title":"AIDS"},{"issue":"9","key":"10.1016\/j.sapharm.2024.04.019_bib15","article-title":"Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs","author":"Platt","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.sapharm.2024.04.019_bib17","unstructured":"Arizona Revised Statue \u00a7 13-3415."},{"issue":"6","key":"10.1016\/j.sapharm.2024.04.019_bib18","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.japh.2022.07.003","article-title":"Access to community pharmacies: a nationwide geographic systems cross-sectional analysis","volume":"62","author":"Berenbrok","year":"2022","journal-title":"J Am Pharmaceut Assoc"},{"issue":"1 suppl","key":"10.1016\/j.sapharm.2024.04.019_bib19","doi-asserted-by":"crossref","first-page":"128S","DOI":"10.1177\/0033354920921817","article-title":"State laws governing syringe services programs and participant syringe possession, 2014-2019","volume":"135","author":"Fern\u00e1ndez-Vi\u00f1a","year":"2020","journal-title":"Publ Health Rep"},{"issue":"6, Suppl 2","key":"10.1016\/j.sapharm.2024.04.019_bib20","first-page":"S77","article-title":"Impact of increased syringe access: preliminary findings on injection drug user syringe source, disposal, and pharmacy sales in Harlem, New York","volume":"42","author":"Fuller","year":"2002","journal-title":"J Am Pharmaceut Assoc"},{"issue":"8","key":"10.1016\/j.sapharm.2024.04.019_bib21","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1089\/apc.2015.0017","article-title":"Evaluation of pharmacy-based HIV testing in a high-risk New York community","volume":"29","author":"Amesty","year":"2015","journal-title":"AIDS Patient Care STDS"},{"issue":"2","key":"10.1016\/j.sapharm.2024.04.019_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1081\/JA-120016563","article-title":"Integrating qualitative and quantitative methods: comparing HIV-related risk behaviors among Puerto Rican drug users in Puerto Rico and New York","volume":"38","author":"Deren","year":"2003","journal-title":"Subst Use Misuse"},{"issue":"3","key":"10.1016\/j.sapharm.2024.04.019_bib23","doi-asserted-by":"crossref","DOI":"10.1177\/003335491312800303","article-title":"Achieving pharmacy based public health: call for public health engagement","volume":"128","author":"Meyerson","year":"2013","journal-title":"Publ Health Rep"},{"key":"10.1016\/j.sapharm.2024.04.019_bib24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.drugpo.2018.02.024","article-title":"Predicting pharmacy syringe sales to people who inject drugs: policy practice and perceptions","volume":"56","author":"Meyerson","year":"2018","journal-title":"Int J Drug Pol"},{"key":"10.1016\/j.sapharm.2024.04.019_bib25","article-title":"Feasibility of a pharmacy-based harm reduction intervention to reduce opioid overdose, HIV and hepatitis C \u2013 Indiana","author":"Meyerson","year":"2019","journal-title":"Res Admin Pharm"},{"issue":"4","key":"10.1016\/j.sapharm.2024.04.019_bib26","first-page":"e17","volume":"59","year":"2019","journal-title":"J Am Pharm Assoc JAPhA"},{"key":"10.1016\/j.sapharm.2024.04.019_bib27","unstructured":"American Public Health Association. Defining and Implementing a Public Health Response to Drug Use and Misuse. Policy Number 201312 [online]: https:\/\/www.apha.org\/policies-and-advocacy\/public-health-policy-statements\/policy-database\/2014\/07\/08\/08\/04\/defining-and-implementing-a-public-health-response-to-drug-use-and-misuse#:\u223c:text=Current%20APHA%20policy%20in%20this,for%20injection%20of%20illicit%20substances Accessed April 17, 2024.."},{"issue":"3","key":"10.1016\/j.sapharm.2024.04.019_bib28","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/QAI.0000000000001098","article-title":"County-level vulnerability assessment for rapid dissemination of HIV or HCV infections among persons who inject drugs, United States","volume":"73","author":"Van","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"49","key":"10.1016\/j.sapharm.2024.04.019_bib29","article-title":"Come Back when You\u2019re Infected: secret shopper study of pharmacy syringe sales in Arizona, USA 2023","volume":"21","author":"Russell","year":"2024","journal-title":"BMC (Biomed Chromatogr): Harm Reduct J"},{"issue":"4","key":"10.1016\/j.sapharm.2024.04.019_bib30","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/jurban\/jth149","article-title":"A multistate trial of pharmacy syringe purchase","volume":"81","author":"Compton","year":"2004","journal-title":"J Urban Health"},{"issue":"57","key":"10.1016\/j.sapharm.2024.04.019_bib31","first-page":"1","article-title":"I could take the judgement if you could just provide the service: non-prescription syringe purchase experience in Arizona pharmacies","volume":"16","author":"Meyerson","year":"2019","journal-title":"BMC Harm Reduction"},{"key":"10.1016\/j.sapharm.2024.04.019_bib32","first-page":"S40","article-title":"Individual and structural influences shaping pharmacists' decisions to sell syringes to injection drug users in Atlanta, Georgia","volume":"42","author":"Taussig","year":"2002","journal-title":"J Am Pharmaceut Assoc"},{"issue":"6 Supp 2","key":"10.1016\/j.sapharm.2024.04.019_bib33","first-page":"S52","article-title":"Pharmacist ambivalence about sale of syringes to injection drug users","volume":"42","author":"Reich","year":"2002","journal-title":"J Am Pharmaceut Assoc"},{"issue":"1","key":"10.1016\/j.sapharm.2024.04.019_bib34","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/08897077.2021.2010162","article-title":"Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies","volume":"43","author":"Green","year":"2022","journal-title":"Subst Abuse"},{"issue":"1","key":"10.1016\/j.sapharm.2024.04.019_bib35","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13722-024-00452-y","article-title":"Implementing a pharmacist-integrated collaborative model of medication treatment for opioid use disorder in primary care: study design and methodological considerations","volume":"19","author":"McLeman","year":"2024","journal-title":"Addiction Sci Clin Pract"},{"issue":"1","key":"10.1016\/j.sapharm.2024.04.019_bib36","doi-asserted-by":"crossref","first-page":"P374","DOI":"10.1016\/j.japh.2022.09.004","article-title":"Pilot implementation of the PharmNet naloxone program in an independent pharmacy","volume":"63","author":"Eldridge","year":"2022","journal-title":"J Am Pharmaceut Assoc"},{"key":"10.1016\/j.sapharm.2024.04.019_bib37","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/1533256X.2017.1304946","article-title":"Effects and durability of an SBIRT training curriculum for first-year MSW students","volume":"17","author":"Carlson","year":"2017","journal-title":"J Soc Work Pract Addict"},{"issue":"8","key":"10.1016\/j.sapharm.2024.04.019_bib38","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3928\/01484834-20160715-02","article-title":"Curricular innovations in tobacco cessation education for prelicensure baccalaureate nursing students","volume":"55","author":"Schwindt","year":"2016","journal-title":"J Nurs Educ"},{"issue":"4","key":"10.1016\/j.sapharm.2024.04.019_bib39","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3928\/01484834-20160316-10","article-title":"If you teach it, they will screen: advanced practice nursing students' use of screening and brief intervention in the clinical setting","volume":"55","author":"Agley","year":"2016","journal-title":"J Nurs Educ"},{"issue":"4","key":"10.1016\/j.sapharm.2024.04.019_bib40","doi-asserted-by":"crossref","first-page":"765","DOI":"10.4300\/JGME-D-14-00288.1","article-title":"Screening, brief intervention, and referral to treatment (SBIRT) and motivational interviewing for PGY1 medical residents","volume":"6","author":"Agley","year":"2014","journal-title":"J Grad Med Educ"},{"issue":"8","key":"10.1016\/j.sapharm.2024.04.019_bib41","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.puhe.2014.05.011","article-title":"Assessing the relationship between medical residents' perceived barriers to SBIRT implementation and their documentation of SBIRT in clinical practice","volume":"128","author":"Agley","year":"2014","journal-title":"Publ Health"},{"issue":"1","key":"10.1016\/j.sapharm.2024.04.019_bib42","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.japh.2022.09.004","article-title":"Pilot implementation of the PharmNet naloxone program in an independent pharmacy","volume":"63","author":"Eldridge","year":"2023","journal-title":"J Am Pharmaceut Assoc"},{"issue":"6","key":"10.1016\/j.sapharm.2024.04.019_bib43","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s10461-013-0427-y","article-title":"We can do more than just sell the test: pharmacist perspectives about over the counter rapid HIV tests","volume":"17","author":"Meyerson","year":"2013","journal-title":"AIDS Behav"},{"key":"10.1016\/j.sapharm.2024.04.019_bib44","series-title":"ASAP Module 1: Overview of Harm Reduction Pharmacy Practice","author":"Meyerson","year":"2022"},{"key":"10.1016\/j.sapharm.2024.04.019_bib45","author":"Meyerson"},{"key":"10.1016\/j.sapharm.2024.04.019_bib46","article-title":"ASAP module 3: state laws and policies governing harm reduction pharmacy practices","author":"Meyerson","year":"2022","journal-title":"Preparation to be Harm Reduction Pharmacies"},{"key":"10.1016\/j.sapharm.2024.04.019_bib47","article-title":"Implementation documentation and process assessment of the PharmNet pilot randomized trial: an observational report","volume":"8","author":"Eldridge","year":"2024","journal-title":"JMIR Form Res"},{"issue":"10","key":"10.1016\/j.sapharm.2024.04.019_bib48","doi-asserted-by":"crossref","DOI":"10.2196\/42373","article-title":"The PharmNet harm reduction intervention for community pharmacies: protocol for a pilot randomized, controlled trial","volume":"11","author":"Eldridge","year":"2022","journal-title":"JMIR Research Protocols"},{"issue":"2","key":"10.1016\/j.sapharm.2024.04.019_bib49","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.japh.2021.10.015","article-title":"Exploration of pharmacist comfort with harm reduction behaviors: cross-sectional latent class analysis","volume":"62","author":"Agley","year":"2022","journal-title":"J Am Pharmacists Assoc"},{"key":"10.1016\/j.sapharm.2024.04.019_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2019.06.036","article-title":"Clarity out of chaos: use of theory in implementation research","volume":"283","author":"Damschroder","year":"2020","journal-title":"Psychiatr Res"},{"key":"10.1016\/j.sapharm.2024.04.019_bib51","article-title":"Implementation documentation and process assessment of the PharmNet pilot randomized trial: an observational report","volume":"8","author":"Eldridge","year":"2024","journal-title":"JMIR Form Res"},{"issue":"6","key":"10.1016\/j.sapharm.2024.04.019_bib52","article-title":"The policy landscape for naloxone distribution in four states highly impacted by fatal opioid overdoses","volume":"March","author":"Bohler","year":"2023","journal-title":"Drug Alcohol Depend Rep"},{"issue":"2","key":"10.1016\/j.sapharm.2024.04.019_bib53","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1353\/hpu.2021.0107","article-title":"Insufficient access: naloxone availability to laypersons in Arizona and Indiana","volume":"32","author":"Meyerson","year":"2021","journal-title":"J Health Care Poor Underserved"},{"key":"10.1016\/j.sapharm.2024.04.019_bib54","series-title":"State Subsidies for Naloxone Purchase through Insurance","year":"2023"},{"key":"10.1016\/j.sapharm.2024.04.019_bib55","unstructured":"Meyerson BE, Richter S, Gordon R, Chang EY, Vadiei, N, Higbie E, Samorano S, Pal AA, Seckar-Martinez A, Newgass K, Lorenz H, Garnett I. Pharmacy Harm Reduction Services to Reduce Overdose. (In review)."}],"container-title":["Research in Social and Administrative Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551741124001578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551741124001578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T19:47:06Z","timestamp":1718480826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551741124001578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":53,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1551741124001578"],"URL":"https:\/\/doi.org\/10.1016\/j.sapharm.2024.04.019","relation":{},"ISSN":["1551-7411"],"issn-type":[{"value":"1551-7411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ASAP: A pharmacy-level intervention to increase nonprescription syringe sales to reduce bloodborne illnesses","name":"articletitle","label":"Article Title"},{"value":"Research in Social and Administrative Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sapharm.2024.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}